Subcutaneous tissue involvement in idiopathic inflammatory myopathies: Systematic literature review including three new cases and hypothetical mechanisms.
Calcinosis
Dermatomyositis
Idiopathic inflammatory myopathy
Lipodystrophy
Mesenchymal stem cell
Panniculitis
Journal
Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
03
01
2023
accepted:
29
01
2023
pubmed:
4
2
2023
medline:
23
3
2023
entrez:
3
2
2023
Statut:
ppublish
Résumé
Involvement of subcutaneous tissue in idiopathic inflammatory myopathies (IIM) is poorly known. We conducted a systematic review of the literature regarding panniculitis and lipodystrophy/lipoatrophy in juvenile and adult IIM via PubMed/Medline, Embase and Scopus databases. Three local observations are included in this review. Epidemiological, clinical, paraclinical and therapeutic data were collected. Panniculitis appears to be more common in adults than in juveniles. It was mainly localised in the upper and lower limbs. Panniculitis improved in most cases with steroids and panniculitis and myositis had a similar course in 83.3% and 72.2% of cases in juveniles and adults, respectively. Lipodystrophy appeared to be more frequent in juveniles and was only observed in dermatomyositis in both juveniles and adults. Lipodystrophy was mainly partial in juveniles and adults. The median time from myositis to the diagnosis of lipodystrophy was 6 years [0-35] and 2.5 years [0-10] in juveniles and adults, respectively. Lipodystrophy was associated with anti-TIF1 gamma auto-antibody positivity, a polycyclic/chronic course of myositis and the occurrence of calcinosis and might be an indicator of poor disease control. Adipose tissue involvement, particularly lipodystrophy, occurs almost exclusively in dermatomyositis. The insidious onset and lack of awareness of the diagnosis may underestimate its prevalence. Larger studies are needed to identify possible risk factors in these patients, to better potential underlying pathophysiological process, in order to discuss potential therapeutic targets.
Identifiants
pubmed: 36736986
pii: S1568-9972(23)00018-6
doi: 10.1016/j.autrev.2023.103284
pii:
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Systematic Review
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103284Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.